Skip to main content

Table 2 Adverse events

From: Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

Adverse event

N (%), tot = 140 patients

G3–4 N (%), tot = 140 patients

Cutaneous

52 (37)

5 (4)

 Pruritus

22 (16)

3 (2)

 Rash

24 (17)

2 (1)

 Vitiligo

6 (4)

0

Gastrointestinal

30 (21)

21 (15)

 Diarrhea

21 (15)

19 (14)

 Pancreatitis or lipase/amylase increase

5 (4)

2 (1)

 Nausea/vomit

3 (2)

0

 Constipation

1 (1)

0

Constitutional symptoms

21 (15)

0

 Fatigue

13 (9)

0

 Fever

7 (5)

0

 Headache

1 (1)

0

Endocrine disorders

12 (9)

11 (8)

 Hypophysitis

10 (7)

10 (7)

 Thyroiditis

1 (1)

0

 Hyperglycemia

1 (1)

1 (1)

Other

9 (6)

1 (1)

 Arthralgia

5 (4)

1 (1)

 Hepatotoxicity

2 (1)

0

 Anemia

1 (1)

0

 Posterior uveitis

1 (1)

0

  1. The most frequent adverse events by all grades were cutaneous toxicity. On the other hand, gastrointestinal events accounted for the majority of severe (G3–4 according to the common terminology criteria for adverse events) toxicities. Patients may have more than one toxicity event, in particular, out of 140 patients, 65 (46%) experienced some AEs and of them, 49 had more than one AE, for a total of 124 total recorded adverse events